TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency.
about
Mitochondrial Trifunctional Protein Defects: Clinical Implications and Therapeutic ApproachesTat-Mediated Peptide Intervention in Analgesia and Anesthesia.Potential therapeutic benefits of strategies directed to mitochondria.TAT opens the door.TAT fusion protein transduction into isolated mitochondria is accelerated by sodium channel inhibitors.Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications.Towards the development of an enzyme replacement therapy for the metabolic disorder propionic acidemia.The approaches for manipulating mitochondrial proteomeTransduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.Therapeutic applications of the TAT-mediated protein transduction system for complex I deficiency and other mitochondrial diseases.Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling.Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.Breaking in and busting out: cell-penetrating peptides and the endosomal escape problem.TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells.Elevated plasma citrulline: look for dihydrolipoamide dehydrogenase deficiency.Import of TAT-conjugated propionyl-CoA carboxylase using models of propionic acidemia.Mitochondriopathien – neue Trends in Diagnostik und Therapie
P2860
Q28972544-134BA578-8855-4C57-BAD6-1A2AAF4D526EQ34054988-ED84970F-DBA7-4B6C-AD6D-9B3AAEC4AE34Q34117168-AC5E79C2-B4D1-4FEA-B7A3-08D6EDBA1572Q34339371-96F9CC7D-53C4-4F0B-BBDF-F87EF83E1ABBQ34593991-869B4EC1-E481-40F8-872F-A4248E9A633AQ34989407-E69BDBE7-E15A-4122-92C1-390AACB7354EQ35052617-8AFB5117-7D55-48E6-87E4-5A68E19E20C5Q37141630-19817CD2-E528-41C2-A7A7-B633528B197FQ37764798-4AE5AC1E-3F0D-43F8-8AFE-1E1D71C21E43Q37923355-C5D024EE-98D9-4748-B461-2C57AC030DC4Q38566683-C0B30AFC-A5DC-4B8D-9CDB-F30828157551Q41661766-2144D850-EFC4-4C13-B3A8-B08265EB2E3FQ41967722-2E3D32D9-FCD9-4DBF-88A7-22426E62B689Q42255378-937ED246-AC0C-494A-8CBD-D4827543AA82Q47266824-EBACB6A4-10D9-4312-8806-E6B870F3EFE9Q47984413-E590BBA5-129A-4C24-AEF2-699B4194A1A4Q49597712-9A8FE721-5C2D-47E3-BE2F-01A1E9A14C08Q57251779-6732D3D2-FBDA-4EFD-9F83-9553A5E0170C
P2860
TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@en
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@nl
type
label
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@en
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@nl
prefLabel
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@en
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@nl
P2093
P356
P1433
P1476
TAT-mediated delivery of LAD r ...... patients with LAD deficiency.
@en
P2093
Haya Lorberboum-Galski
Matan Rapoport
Orly Elpeleg
P304
P356
10.1038/MT.2008.4
P50
P577
2008-02-05T00:00:00Z